ORIC Pharmaceuticals (ORIC) CFO Piscitelli Sells $189K of Stock

Oric Pharmaceuticals, Inc. Chief Financial Officer Dominic Piscitelli sold 14,000 shares of the company on October 20, 2026. The transaction was revealed in a Form 4 filing submitted to the Securities and Exchange Commission.

ORIC ORIC Pharmaceuticals, Inc.

$13.85 ▲ +69.52% year to date

1M 3M YTD

Daily close · Oct 21, 2026

Inside Dominic Piscitelli's Oric Pharmaceuticals Trade

Dominic Piscitelli parted with the shares at an average price of $13.53, totaling roughly $189,390. This planned sale cut his direct holding by 16.7% down to 69,828 shares. Insider sales executed through a pre-arranged plan are often scheduled months in advance to cover tax obligations or for personal financial planning.

Other Institutional Activity in Oric Pharmaceuticals

Other large funds adjusted their positions during the middle of the year. Nextech Invest, Ltd. kept its holdings steady with 7,162,637 shares valued at about $99.2 million. EcoR1 Capital, LLC maintained its stake at 6,728,116 shares worth roughly $93.2 million. Viking Global Investors, L.P. trimmed its holdings by 697,780 shares, ending with 5,126,762 shares valued at about $71.0 million following a 12.0% decrease. SR One Capital Management, LP grew its stake by 100,236 shares to hold 4,615,384 shares worth about $63.9 million, marking a 2.2% increase. Venrock Adviser, LLC held steady with 4,319,765 shares worth roughly $59.8 million.

ORIC Pharmaceuticals, Inc. Stock Holds Steady

The stock recently traded around $13.78, sitting 6.4% above its 50-day moving average of $12.96 and 24.4% above its 200-day moving average of $11.07. Shares trade below their 52-week high of $14.68 and well above their 52-week low of $7.23. The company has a market capitalization of roughly $1.44 billion and a beta of 0.98.

Recent Earnings

For the trailing twelve months, the company posted an earnings per share loss of $1.32 and reported a net margin of 0.0% alongside a return on equity of -39.8%. The next financial report is scheduled for November 12, 2026.

Insider Buying and Selling at ORIC Pharmaceuticals, Inc.

Director Richard A. Heyman sold 300 shares on July 6, 2026, at $12.00 each for $3,600, and followed up by selling 13,100 shares on July 24, 2026, at $12.02 each for $157,462. Dominic G. Piscitelli previously sold 77,000 shares on August 26, 2026, at $13.69 each for about $1.05 million, and 13,400 shares on September 28, 2026, at $13.53 each for $181,258.

Analysts Set New Price Targets

On August 10, 2026, HC Wainwright & Co. maintained a buy rating and raised its price target from $25.00 to $27.00. BTIG initiated coverage with a buy rating and a $26.00 price target on September 23, 2026. Leerink Partners initiated coverage with an outperform rating and a $26.00 price target on October 5, 2026. JP Morgan maintained an overweight rating on October 14, 2026, lifting its target from $23.00 to $26.00. The stock carries a consensus recommendation of strong buy with a mean price target of $21.64 across 14 analyst opinions.

About Oric Pharmaceuticals

Oric Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California. The firm focuses on discovering and developing new therapies designed to stop cancer cells from developing resistance to existing treatments.

Bottom Line

Investors will watch the upcoming earnings release on November 12, 2026, for updates on the firm's drug pipeline and cash runway. Additional Form 4 filings will show whether other executives continue trimming their holdings following this transaction.